You are currently browsing the archives for 30 May 2016.
Displaying 1 entry.

Kamada an Orphan Drug Designation by both the U.

Kamada an Orphan Drug Designation by both the U.S. FDA and the EMEA for aerosol received AAT for the treatment of congenital emphysema and cystic fibrosis. ODD designation, and subsequent ODD status, present significant commercial advantages in the development, registration and distribution of the product throughout its life cycle, particularly the exclusive marketing rights for a period of 7 years in the USA and 10 years in Europe, should Kamada the first to the successful completion of clinical trials and obtain regulatory approval for this indication.

About KamadaKamada is a public biopharmaceutical company developing, manufacturing and marketing a range of specialty life-saving therapeutics using its proprietary chromatographic purification technologies. Licensed and marketed in more than 15 countries, some of these specialty therapeutics hold registered and pending patents and are currently in advanced clinical trials.